Regenerative Medicine 2018 Global Market to Reach US$ 66 billion and Growing at CAGR of 23.3% by 2022

Regenerative Medicine Market
WiseGuyReports.Com Publish a New Market Research Report On –“ Regenerative Medicine 2018 Global Market to Reach US$ 66 billion and Growing at CAGR of 23.3% by 2022”.

 

This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $66 billion by 2022, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2022. Tissue engineering is forecast to grow at a CAGR of x% to 2022 and potentially reach $x billion. This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 680 pages.

 

Get a Sample Report@   https://www.wiseguyreports.com/sample-request/3229169-global-regenerative-medicine-market-analysis-forecast-to-2022

For more information or any query mail at sales@wiseguyreports.com

 

•An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies. 
• Global regenerative medicine market, global breakdown, application breakdown and leading market players 
• Detailed account of the stem cell industry market by geography, indication and company profiles 
• Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space 
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine 
• Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies. 
• Insight into the biobanking industry globally and its impact on the overall market 
• Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies 
• Financial market forecast through 2022 with CAGR values of all market segments outlined in the objective 
• SWOT analysis of the global market 
• Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe

 

Complete Report Details @   https://www.wiseguyreports.com/reports/3229169-global-regenerative-medicine-market-analysis-forecast-to-2022

 

Table Of Contents – Major Key Points

1.0 Report Synopsis 
    1.1 Objectives of Report 
    1.2 Executive Summary 
    1.2 Key Questions Answered in this Report 
    1.3 Data Sources and Methodology 

2.0 Introduction 
    2.1 Gurdon and Yamanaka Share the Nobel Prize 
    2.2 Stem Cell Clinical Trials: Initiated in 2010 
    2.3 Types of Stem Cells 
    2.4 Adult (Tissue) Stem Cells 
    2.5 Pluripotent Stem Cells 
    2.6 Somatic Cell Nuclear Transfer (SCNT) 
    2.7 Induced pluripotent Stem Cells (iPSC) 
    2.8 Mesenchymal Cells 
      2.8.1 MSCs in the Bone Marrow Stroma 
      2.8.2 Isolation, Marker Specificity and Functional Properties of MSCs 
      2.8.3 Oxygen Concentration and MSC Culture 
      2.8.4 Assays to Define MSCs 
      2.8.5 Differentiation Potential of MSCs 
      2.8.6 Therapeutic Potential of MSCs 
      2.8.7 Mesenchymal Stem Cells & Chronic Disease 
      2.8.8 MSCs and Amylotrophic Lateral Sclerosis 
      2.8.9 MSCs and Parkinson’s Disease 
      2.8.10 MSCs and Alzheimer Disease 
      2.8.11 MSCs and Rheumatoid Arthritis 
      2.8.12 MSCs and Type 1 Diabetes 
      2.8.13 MSCs and Cardiovascular Disease 
    2.9 Hematopoietic Stem and Progenitor Cells 
      2.9.1 In Vivo Assays for Hematopoietic Stem Cells 
      2.9.2 In Vitro Assays for Hematopoietic Stem and Progenitor Cells 
      2.9.3 Isolation of Hematopoietic Stem and Progenitor Cells 
      2.9.4 Culture of Hematopoietic Cells 
      2.9.5 Therapeutic uses of Hematopoietic Cells 
    2.10 Umbilical Cord Stem Cells 
    2.11 Heart Stem Cells 
      2.11.1 Cutting Edge Research in Heart Stem Cells 
    2.12 Mammary Stem Cells 
      2.12.1 Defining the Mammary Stem Cell 
      2.12.2 Influence of Model System on Stem Cell Identification 
      2.12.3 Breast Cancer Stem Cells 
    2.13 Neural Stem Cells 
      2.13.1 Identification of Neural Stem Cells 
      2.13.2 Function of Neural Stem Cells in Vivo 
      2.13.3 Neural Stem Cell Culture Systems 
      2.13.4 Isolation Strategies for Neural Stem Cells 
      2.13.5 Brain Tumour Stem Cells 
      2.13.6 Cutting Edge Research in Neural Stem Cells 
    2.14 Stem Cell Applications in Retinal Repair 
      2.14.1 Embryonic Stem Cells as Retina Therapeutics 
      2.14.2 Induced Pluripotent Stem Cells as Retina Therapeutics 
      2.14.3 Adipose Derived Mesenchymal Stem Cells as Retina Therapeutics 
    2.15 Liver Stem Cells 
    2.16 Gut Stem Cells 
    2.16 Pancreatic Stem Cells 
    2.17 Epidermal Stem Cells 

3.0 Stem Cells and Clinical Trials 
    3.1 Introduction 
    3.2 Pluripotent Stem Cells 
    3.3 Limbal Stem Cells 
    3.4 Neural Stem Cells 
    3.5 Endothelial Stem or Progenitor Cells 
    3.6 Placental Stem Cells 
    3.7 Why Do Stem Cell Clinical Trials Fail? 
    3.8 What is the Future of Stem Cell Trials? 
    3.9 Cutting Edge Stem Cell Clinical Trials 
    3.10 Ocata Therapeutics Current Stem Cell Trials 
    3.11 CHA Biotech Current Stem Cell Trials 
    3.12 Pfizer Current Stem Cell Trials 
    3.13 GSK Current Stem Cell Trials 
    3.14 Bayer Current Stem Cell Trials 
    3.15 Mesoblast International Current Stem Cell Trials 
    3.16 Millennium Pharmaceutical Current Stem Cell Trial 
    3.17 AstraZeneca Current Stem Cell Trials 
    3.18 Merck Current Stem Cell Trials 
    3.19 Chimerix Current Stem Cell Trials 
    3.20 Eisai Current Stem Cell Trials 
    3.21 SanBio Current Stem Cell Trials 
    3.22 Celgene Current Stem Cell Trials 
    3.23 StemCells Current Stem Cell Trials 
    3.24 Genzyme (Sanofi) Current Stem Cell Trials 
    3.25 Teva Current Stem Cell Trials 
    3.26 MedImmune Current Stem Cell Trials 
    3.27 Janssen Current Stem Cell Trials 
    3.28 Seattle Genetics Current Stem Cell Trials 
    3.29 Baxter Healthcare Current Stem Cell Trials 
    3.30 InCyte Corp Current Stem Cell Trials 

4.0 Stem Cells, Disruptive Technology, Drug Discovery & Toxicity Testing 
    4.1 Introduction 
    4.2 Case Study: Genentech and Stem Cell Technology 
    4.3 3D Sphere Culture Systems 
    4.4 Stem Cells and High Throughput Screening 
      4.4.1 Embryonic Stem Cells 
      4.4.2 Adult Stem Cells 
      4.4.3 Opportunities & Challenges 
    4.5 Genetic Instability of Stem Cells 
    4.6 Comprehensive in Vitro Proarrhythmia Assay (CiPA) & Cardiomyocytes 
    4.8 Coupling Precise Genome Editing (PGE) and iPSCs 
    4.9 Stem Cells & Toxicity Testing 
      4.9.1 Hepatotoxicity and iPSCs 
      4.9.2 Cardiotoxicity and iPSCs 
      4.9.3 Neurotoxicity and iPSCs 
    4.10 Stem Cell Disease Models 
    4.11 Defining Human Disease Specific Phenotypes 
      4.11.1 Molecular Phenotypes for Disease Modelling 
      4.11.2 Cellular Phenotypes for Disease Modelling 
      4.11.3 Physiological Phenotypes for Disease Modelling 
      4.11.4 Parkinson’s Disease 
      4.11.5 Alzheimer’s Disease 
      4.11.6 Amyotrophic Lateral Sclerosis 
      4.11.7 Huntington’s Disease 
      4.11.8 Spinal Muscular Atrophy 
      4.11.9 Down Syndrome 
      4.11.10 Cystic Fibrosis 
      4.11.11 Colorectal Cancer 
    4.12 Advantages of Stem Cell Derived Cells & Tissues for Drug Screening 

5.0 Stem Cell Biomarkers 
    5.1 Pluripotent Stem Cell Biomarkers 
    5.2 Mesenchymal Stem Cell Biomarkers 
    5.3 Neural Stem Cell Biomarkers 
    5.4 Hematopoietic Stem Cell Biomarkers 

6.0 Manufacturing Stem Cell Products 
    6.1 Manufacturing Strategies For Stem Cell Products 
    6.2 BioProcess Economics for Stem Cell Products 
    6.3 Capital Investment 
    6.4 Cost of Goods 
    6.5 Bioprocess Economic Drivers & Strategies 
    6.6 hPSC Expansion & Differentiation using Planar Technology 
    6.7 hPSC Expansion using 3D Culture 
    6.8 Microcarrier Systems 
    6.9 Aggregate Suspension 
    6.10 Bioreactor Based Differentiation Strategy 
    6.11 Integrated hPSC Bioprocess Strategy 
    6.12 GMP Regulations and Stem Cell Products 

7.0 Investment & Funding 
    7.1 What do Investors Want from Cell & Gene Therapy Companies? 
    7.2 What Makes a Good Investment? 
    7.3 What Types of Companies do Not Get Investment? 
    7.4 Global Funding 
    7.5 Cell & Gene Therapy Investment Going Forward 
    7.6 What Cell & Gene Companies are the Most Promising in 2018? 
    7.7 Insights into Investing in Cell and Gene Therapy Companies 

Continued…..

For more information or any query mail at sales@wiseguyreports.com

ABOUT US:

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com